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Edited by Robert BaroukiAbstract Typically, chemopreventive agents either inhibit the
cytochrome P450s (CYPs) that are essential for the metabolism
of carcinogens or induce phase II detoxifying enzymes. This
study examined the chemopreventive eﬀect of eugenol on 7,12-
dimethylbenz[a]anthracene (DMBA)-induced DNA damage in
MCF-7 cells. Eugenol inhibited the formation of the DMBA–
DNA adduct in a dose dependent manner. CYP1A1 and
CYP1B1 activity, which catalyze the biotransformation of
DMBA, were strongly inhibited by eugenol. Eugenol also sup-
pressed the CYP1A induction by DMBA through decreased aryl
hydrocarbon receptor activation and subsequent DNA binding.
Furthermore, eugenol increased the expression and activity of
NAD(P)H:quinone oxidoreductase (QR), a major detoxifying
enzyme for DMBA, through NF-E2 related factor2 binding to
antioxidant response element in QR gene. Therefore, eugenol
has a potent protective eﬀect against DMBA-induced genotoxi-
city, presumably through the suppression of the DMBA activa-
tion and the induction of its detoxiﬁcation. These results
suggest that eugenol has potential as a chemopreventive.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Many synthetic and natural compounds that are capable of
modulating of phase I and/or phase II enzymes in the carcino-
gen metabolism are known to interfere with the process of car-Abbreviations: AhR, aryl hydrocarbon receptor; ARE, antioxidant
response element; CYP, cytochrome P450; DMBA, 7,12-dimethyl-
benz[a]anthracene; NAD(P)H, quinone oxidoreductase (QR); EROD,
ethoxyresoruﬁn-O-deethylase; GST, glutathione S-transferase; Nrf2,
NF-E2 related factor2; XRE, xenobiotics response element
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doi:10.1016/j.febslet.2007.01.044cinogenesis [1]. A large number of carcinogens are metabolized
by the cytochrome P450 (CYP) enzymes to chemically reactive
species that covalently bind to the DNA and promote carcino-
genesis. These reactive metabolites may be detoxiﬁed to inac-
tive species by a couple of phase II conjugating enzymes.
Hence, the possible mechanisms of chemoprevention involve
either the inhibition of the CYPs required for the metabolism
of carcinogens, such as the CYP1 family [2] or the induction
of phase II detoxifying enzymes, such as glutathione S-transfer-
ase (GST) and NAD(P)H:quinone oxidoreductase (QR) [1,3].
The induction of phase II enzymes, such as GST and QR, is
also considered to be one of the most important determinants
in cancer susceptibility and is associated with cancer chemopre-
ventive and cytoprotective eﬀects [3]. The transcriptional acti-
vation of the phase II enzymes has been traced to a cis-acting
transcriptional enhancer called antioxidant response element
(ARE). It has been shown that the transcription factor NF-
E2 related factor2 (Nrf2) positively regulates the ARE-medi-
ated expression of the phase II detoxiﬁcation enzyme genes [4].
One of the most important factors determining the sensitiv-
ity to mammary carcinogenesis is the metabolic stage of the
carcinogenic agent. 7,12-Dimethylbenz[a]anthracene (DMBA)
is a polycyclic aromatic hydrocarbon (PAH) that is widely
used as a model chemical carcinogen in rat mammary tumor
model [5]. DMBA is a procarcinogen and requires metabolic
conversion to its ultimate carcinogenic diol epoxide metabo-
lites by oxidation, which is carried out through CYP1A1 and
CYP1B1 [6,7]. The covalent binding of the diol epoxides of
DMBA to DNA is believed to be essential for tumor initiation
[5,8]. Therefore, the extent to which the DNA adducts occurs
after administering DMBA depends on the level of the oxida-
tive metabolism of DMBA due to CYP1 [7]. CYP1A1 and
CYP1B1 expression are mediated by the aryl hydrocarbon
receptor (AhR), which is a cytosolic protein that can be acti-
vated by PAH. DMBA, like other PAHs, binds and activates
the AhR. Upon activation, the ligand-bound AhR translocates
to the nucleus and dimerizes with the AhR nuclear transloca-
tor (ARNT). This protein dimer interacts with a speciﬁc gene
promoter sequence, which is known as the xenobiotic respon-
sive element (XRE), and initiates the transcription of the
CYP1 enzyme family [9,10]. Finally, DMBA can be detoxiﬁed
to inactive metabolites by the action of class pi GST or QR
[11–14].blished by Elsevier B.V. All rights reserved.
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of a number of aromatic plants and their essential oil fractions.
It is widely used as a general antiseptic in medical and dental
practice, agriculture, cosmetics and the food industry, on
account of its potent fungicidal, bactericidal, antioxidant and
anti-inﬂammatory properties [15–17]. Eugenol was also shown
to have antimutagenic activity [18,19] and anticarcinogenic
properties in various animal models [20–22]. In a skin painting
study, eugenol was reported to be eﬀective in inhibiting the
benzo(a)pyrene-induced skin carcinomas and DMBA-croton
oil-induced papillomas [20,21].
Although the anticarcinogenic properties of eugenol have
been demonstrated in animal models, their mechanism of
action is not completely understood. The aim of this study
was to develop an in vitro cell model to examine the mecha-
nisms whereby eugenol exerts its anticarcinogenic eﬀects. The
main focus was on the ability of eugenol to inhibit the forma-
tion of the DNA adducts by DMBA metabolites and to aﬀect
the phase I and phase II enzymes in the MCF-7 cells. These
results suggest that eugenol attenuates the formation of DNA
adducts by DMBA by down-regulating the expression of
CYP1A1 and CYP1B1 and up-regulating the expression of QR.2. Materials and methods
2.1. Materials
All the chemicals and cell culture materials were obtained from the
following sources: eugenol and DMBA (>99% purity: Sigma–Aldrich
Chemicals); [3H]DMBA and Western blotting detection reagents
(ECL) (Amersham Pharmacia Biotech.); 7-ethoxyresoruﬁn and resoru-
ﬁn (Pierce Chemical Co.); MTTbased colorimetric assay kit (Roche
Co.); LipofectAMINE Plus, RPMI 1640, fetal bovine serum, penicil-
lin-streptomycin solution (Life Technologies, Inc.); luciferase assay
system (Promega); pCMV-b-gal (Clonetech); Nrf2, QR, and b-actin
antibodies (Abcam). All other chemicals used were of analytical grade
or the highest grade available.
2.2. Cell culture
MCF-7 cells (American Type Culture Collection, Manassas, VA,
USA) were grown in RPMI 1640 supplemented with 2 mM of gluta-
mine and 10% fetal bovine serum at 37 C in an atmosphere containing
5% CO2. Both eugenol and DMBA were dissolved in dimethylsulfox-
ide (DMSO). Stock solutions of these chemicals were added directly to
the culture media. The control cells were treated with DMSO only. The
ﬁnal concentration of the solvent was always <0.2%. The cell viability
was assessed using a MTT assay according to the manufacturer’s
instructions.
2.3. Analysis of DMBA–DNA adduct formation
Analysis of DMBA–DNA adduct formation was performed as
described elsewhere [23]. Conﬂuent cultures of MCF-7 cells in six-well
plates were exposed to 0.4 lM [3H]DMBA in the presence or absence
of eugenol for 16 h. The DNA was extracted, quantiﬁed and the
amount of tritiated metabolite bound to the DNA was measured using
a method described elsewhere [23]. The amount and purity of the
extracted DNA was determined by measuring the absorbance at
260 nm/or 280 nm. DNA samples attaining a 260 nm/280 nm ratio of
>1.9 were used for scintillation counting. The percentage inhibition
of DNA adduct formation by eugenol was calculated using the follow-
ing equation: % inhibition = 100  [(dpm/mg DNA test cells/dpm/mg
DNA control cells) · 100].
2.4. 7-Ethoxyresoruﬁn-O-deethylase assay in intact MCF-7 cells
The 7-ethoxyresoruﬁn-O-deethylase (EROD) activity in the MCF-7
cells was determined as a measure of the CYP1A1 and CYP1B1 activ-
ities. The MCF-7 cells in 48-well plates were treated with DMBA in the
presence or absence of eugenol for 18 h. After incubation, the mediumwas removed and the wells were washed twice with fresh medium. The
EROD activity in the intact cells was determined using the method
described elsewhere [24]. The ﬂuorescence was measured for 30 min
at an excitation wavelength of 530 nm and an emission wavelength
of 590 nm in a FL-600 multi plate ﬂuorescence reader (BIO-TEK,
USA).
2.5. Enzyme activity assay
The NAD(P)H:quinone oxidoreductase (QR) activity was deter-
mined using menadione as a substrate as previously described [25].
The protein concentration was determined using the bicinchoninic acid
protein assay (Pierce).
2.6. Reverse transcriptase polymerase chain reaction analysis for
CYP1A1 and CYP1B1 mRNA expression
The total RNAwas extracted from the cells that had been treatedwith
DMBA in the presence or absence of eugenol. cDNA synthesis, semi-
quantitative polymerase chain reaction (RT-PCR) for CYP1A1,
CYP1B1 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
mRNA, and analysis of the results were performed as described else-
where [26]. A cycle number that fell within the exponential range of
the CYP1A1 (25 cycles), CYP1B1 (23 cycles) and GAPDH (17 cycles)
responses was used. The PCR products were electrophoresed through
a 1.8% agarose gel and visualized by ethidium bromide staining and
UV irradiation. The gel images were captured on aGelDoc ImageAnal-
ysis System (Kodak) and the PCR product yields were normalized to
GAPDH after a quantitative estimation using NIH Image software
(Bethesda,MD). Prior to analysis the PCRproduct band intensitieswere
checked to ensure that they had not reached the saturation intensity.
2.7. Transfection of plasmids and measurement of luciferase activity
CYP1A1-XRE-driven luciferase reporter plasmid (1306 to 824 of
the murine CYP1A1) [24] containing four XRE was used to examine
the speciﬁc activation of XRE. Human QR-ARE-luciferase reporter
plasmid constructs containing ARE binding sites of QR gene was
kindly provided by Dr. Masayuki Yamamoto (University of Tsukuba,
Japan) [27]. The MCF-7 cells were co-transfected transiently with
0.2 lg of pCMV-b-gal and 1 lg of XRE-regulated luciferase reporter
plasmid (CYP1A1-XRE-Luc) or ARE-regulated luciferase reporter
plasmid (QR-ARE-Luc) per well using LipofectAMINE Plus. After
16 h, the medium was removed, and the cells were treated with or with-
out DMBA and eugenol. After exposing the cells for 18 h, they were
washed with PBS and lysed. The supernatants were assayed for their
luciferase and b-galactosidase activity. The luciferase activity was
determined using a luciferase assay system (Promega) in accord with
the manufacturer’s instructions using a luminometer (Luminoscan
Ascent, Thermo electron Co.). The b-galactosidase assay was carried
out as described elsewhere [24]. The luciferase activity was normalized
to the b-galactosidase activity and is expressed as a proportion of the
activity detected in the vehicle controls.
2.8. Western blot analysis
After treatment, the cell lysates were prepared and resolved by 10%
SDS–polyacrylamide gel electrophoresis (SDS–PAGE), which was fol-
lowed by electroblotting onto a polyvinylidene diﬂouride membrane.
The membranes were probed with the appropriate primary antibodies
followed by incubation with the horseradish peroxidase-conjugated
secondary antibody. The blots were probed with an ECL Western blot
detection system according to the manufacturer’s instructions.
2.9. Preparation of nuclear extracts and electromobility gel shift assay
The nuclear extracts were prepared and an electromobility gel shift
assay (EMSA) was performed according to a previously published
method [24]. The synthetic DNA oligonucleotides containing the
AhR-binding site of the XRE [28] were labeled with [32P]ATP. The
nuclear extract was mixed with a gel shift-binding buﬀer, containing
1 mM dithiothreitol and 0.1 mM PMSF, and 1.0 lg of poly (dI Æ dC),
and incubated for 20 min at 20 C prior to adding the 32P-labeled syn-
thetic oligonucleotide (100000 dpm). The DNA–protein complexes
were resolved using a 4% non-denaturating polyacrylamide gel with
a recirculating TAE buﬀer (6.7 mM Tris–HCl containing 3.3 mM
sodium acetate and 1.0 mM EDTA, pH 8.0) followed by autoradio-
graphy.
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All the experiments were repeated at least three times to ensure
reproducibility. The results are expressed as a mean ± S.D., and the
data was analyzed using one-way ANOVA followed by a Dunnett’s
t test for the signiﬁcant diﬀerence. A P value <0.05 was considered sig-
niﬁcant.3. Results
3.1. Inhibition of DMBA–DNA adduct formation
The amount of DNA adduct formation was analyzed by
measuring the level of the tritiated metabolites of DMBA
incorporation into the DNA by scintillation counting. In order
to test the eﬀect of eugenol on the formation of the DNA
adducts, the cells were incubated with eugenol and [3H]DMBA
for 16 h. Eugenol inhibited the formation of the DMBA–DNA
adducts in a dose-dependent manner (Fig. 1). An examination
of the cytotoxicity of eugenol in the cells using a MTT assay
indicated that eugenol had no adverse eﬀects on the cell viabil-
ity (>95% cell viability, Fig. 1). Therefore, the inhibition of the
DMBA–DNA adducts by eugenol was not the result of any
cytotoxicity.
3.2. Inhibition of CYP1A1 and CYP1B1 activity and expression
CYP1A1 and CYP1B1 are key enzymes involved in the acti-
vation of DMBA to the DNA-binding metabolites [7]. DMBA
by itself can increase the expression of CYP1A1 and CYP1B1
through transcriptional activation. Accordingly, in order to
test whether the eugenol can aﬀect the induction of CYP1
activity, the eﬀect of eugenol on CYP1 enzyme activity (repre-
sented by EROD) was measured in the presence of DMBA. As
shown in Fig. 2A, the MCF-7 cells treated with 1 lM DMBA
for 18 h showed signiﬁcantly increased the EROD activity.
Co-treatment of eugenol inhibited the DMBA-induced EROD
activity in a dose-dependent manner, and inhibited the EROD
activity by 50% at a concentration of 10 lM. To test the pos-
sibility that the decrease of CYP1A activity was due to the
change of expression, RT-PCR was performed. The treatment
of MCF-7 cells with 1 lMDMBA for 6 h resulted in the induc-
tion of CYP1A1 and CYP1B1 mRNA. The cells co-treated
with eugenol and DMBA showed signiﬁcant suppression ofDMBA
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independent experiments performed in triplicate. *P < 0.05, **P < 0.01 signiﬁthe DMBA-induced CYP1A1 and CYP1B1 mRNA tran-
scripts, which was dose-dependent (Fig. 2B).
The inhibition of CYP1 activity in Fig. 2A might be, at least
in part, from direct inhibition of these enzymes by eugenol. In
order to test this hypothesis, the eﬀect of eugenol on EROD
activity was determined on microsomal fractions from livers
of 3-methylcholanthrene (3-MC; CYP1 inducer)-treated rats.
Eugenol treatment resulted in a dose-dependent decrease in
EROD activity of the microsomes (Table 1). The speciﬁc inhi-
bition of EROD was conﬁrmed by the treatment of a-napht-
hoﬂavone (1 lM), a known inhibitor of EROD activity.
3.3. Inhibition of AhR transactivation
Our results showed that the expression of CYP1 was sup-
pressed by eugenol. AhR mediate the expressions of CYP1A1
and CYP1B1, and DMBA binds and activates the AhR [9,10].
The eﬀect of eugenol on the transactivation of XRE reporter
gene (pCYP1A1-XRE-Luc) was assessed in order to determine
if eugenol causes the transcriptional inhibition of the CYP1A1
and CYP1B1 genes through AhR activation. The cells were
treated with DMBA and/or eugenol and the XRE-driven lucif-
erase activities were determined. The DMBA treatment caused
an increase in the luciferase activity compared with the control.
However, when the cells were treated simultaneously with
DMBA and eugenol, the DMBA-induced XRE-driven lucifer-
ase activity was signiﬁcantly suppressed by eugenol in a dose-
dependent manner (Fig. 3A). EMSA was carried out to
determine if eugenol could reduce the DMBA-induced XRE
binding activity of AhR. The AhR–XRE binding activity
was increased in the DMBA-stimulated MCF-7 cells than
the controls, which was suppressed by eugenol (Fig. 3B). The
speciﬁcity of this interaction was veriﬁed by the ability of a
200-fold excess of unlabeled XRE oligonucleotide to compete
with the DMBA-induced binding of AhR to 32P-labeled XRE.
3.4. Induction of QR expression
It was reported that chemopreventive agents could induce
phase II gene expression, which is considered to be one of
the important mechanisms for how these agents to protect cells
or organisms against environmental carcinogen insult [3].
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Fig. 2. Inhibitory eﬀects of eugenol on the DMBA-induced EROD activity and CYP1A1 and CYP1B1 mRNA expression. (A) EROD activity. The
cells were treated with 1 lM DMBA and eugenol (lM). After 18 h of treatment, the cells were assayed for their EROD activity. The values are
reported as a mean ± S.D. of three independent experiments performed in triplicate. *P < 0.05, **P < 0.01 signiﬁcantly diﬀerent from DMBA. (B)
RT-PCR analysis of CYPlA1 and CYP1B1 mRNA expression. The cells were treated with 1 lMDMBA and eugenol (lM). After 6 h treatment, the
total RNA was isolated and semi-quantitative RT-PCR was performed. One of three representative experiments is shown. The ratio of the RT-PCR
product of CYP1A1 or CYP1B1 to GAPDH was calculated. Induction-fold is represented as a mean ± S.D. of three separate experiments. *P < 0.05,
**P < 0.01 signiﬁcantly diﬀerent from DMBA.
Table 1
Eﬀects of the eugenol on the microsomal EROD activity
Treatment EROD activity (%)
Control 100 ± 9
Eugenol (10 lM) 72 ± 8
Eugenol (20 lM) 36 ± 5
a-NF (1 lM) 16 ± 3
Rats were treated with 3-methylcholanthrene (3-MC) and microsomes
were isolated. Microsome (10 mg) were incubated with eugenol (10 or
20 lM) or a-naphthoﬂavone (a-NF; 1 lM), and EROD activity was
determined.
752 E.H. Han et al. / FEBS Letters 581 (2007) 749–756epoxide metabolites, which reacts with and damages the DNA.
The DNA-binding metabolite of DMBA is detoxiﬁed mainly
by the action of QR [11,12]. Therefore, the inhibition of
DNA adduct formation could also be a consequence of
enhanced detoxiﬁcation. In order to evaluate this possibility,
the MCF-7 cells were incubated with eugenol for 18 h, and
the QR activities were measured. Eugenol increased the QR
enzymatic activity in a dose-dependent manner (Fig. 4A).
The eﬀect of eugenol on the level of QR protein was investi-
gated by Western blotting experiments. The cells exposed to
eugenol for 12 h showed signiﬁcantly increased levels of QR
(Fig. 4B). This is consistent with the enzyme activity assay
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Fig. 3. Inhibitory eﬀects of eugenol on DMBA-induced AhR transactivation. (A) DMBA-induced XRE-driven luciferase activities. The cells were
transient transfected with the XRE-Luc reporter plasmids, and treated with 1 lM DMBA and eugenol (lM). After 18 h treatment, the cells were
harvested, and luciferase activities were determined. The values are reported as a mean ± S.D. of three independent experiments performed in
triplicate. *P < 0.01, **P < 0.01 signiﬁcantly diﬀerent from DMBA. (B) DMBA-induced AhR–XRE binding activity. The cells were treated with
1 lM DMBA and eugenol (lM). After 3 h treatment, the nuclear extracts were isolated and used in an electromobility shift assay with 32P-labeled
XRE oligonucleotide as probe. The arrow indicates the AhR–XRE complex. Excess XRE; 200-fold excess of nonlabeled XRE.
E.H. Han et al. / FEBS Letters 581 (2007) 749–756 753results. These results show that the induction of QR by euge-
nol appears to be associated with an increase in their enzy-
matic activities.
3.5. Nrf2/ARE activation
It was reported that the induction of the QR occurs at the
transcriptional level and is regulated by a cis-acting element
that is present in the promoters called ARE. Nrf2 is a key tran-
scription factor that binds to the ARE sequences, and has been
implicated in the regulation of phase II enzymes expression [4].
To investigate whether the induction of QR by eugenol is med-
iated via the activation of Nrf2/ARE, MCF-7 cells were trans-
fected with luciferase expression vectors carrying the ARE
sequence of human QR gene. As shown in Fig. 5A, eugenol
potently increased the luciferase activities of the ARE reporter
genes, QR-ARE-Luc (Fig. 5A). This indicates that eugenol
stimulates the expression of the QR through ARE activation.An increase in the nuclear Nrf2 level is required for the activa-
tion of the ARE [4]. The Nrf2 nuclear translocation was mea-
sured by Western blot analysis to conﬁrm that eugenol elicits
the activation of the Nrf2. Treatment of the cells with eugenol
increased the level of Nrf2 in the nuclear fractions (Fig. 5B).
This suggests that the induction of the phase II enzymes by
eugenol is related with Nrf2-mediated ARE activation.4. Discussion
It was reported that eugenol inhibits the mutagenicity of
benzo[a]pyrene and aﬂatoxin B1 [18,29] and has anticarcino-
genic properties against benzo(a)pyrene and DMBA in animal
models [20–22]. Oral administration of eugenol to rats de-
creased the CYP content, arylhydrocarbon hydroxylase activ-
ity and total benzo[a]pyrene hydroxylase activity [18,19]. It
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Fig. 4. Eﬀect of eugenol on QR activity and its expression. (A) QR
activity. The cells were treated with eugenol (lM). After 18 h
treatment, the cells were assayed for QR activity. The values are
reported as a mean ± S.D. of three independent experiments per-
formed in triplicate. *P < 0.05, **P < 0.01 signiﬁcantly diﬀerent from
the control. (B) QR expression. The cells were treated with eugenol
(lM). After 12 h of treatment, the cell lysates were blotted with the
anti-QR or b-actin antibody. Induction-fold is represented as the
mean ± S.D. values of three separate experiments. *P < 0.05,
**P < 0.01 signiﬁcantly diﬀerent from the control.
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Fig. 5. Eﬀect of eugenol on Nrf2/ARE activation. (A) ARE-driven
luciferase activities. The cells were transient transfected with the QR-
ARE reporter plasmids, and treated with eugenol (lM). After 18 h of
treatment, the cells were harvested, and the luciferase activities were
determined. The values are reported as a mean ± S.D. of three
independent experiments performed in triplicate. **P < 0.01 signiﬁ-
cantly diﬀerent from the control. (B) Nuclear translocation of Nrf2.
The cells were treated with eugenol (lM) for 1 h treatment, the nuclear
extracts were isolated and examined by Western Blot analysis using the
Nrf2 speciﬁc antibody.
754 E.H. Han et al. / FEBS Letters 581 (2007) 749–756was also reported that eugenol induces phase II detoxifying en-
zymes such as UDP-glucuronyl transferase, DT-diaphorase
and GST [19,30,31]. Therefore, eugenol is expected to exert
chemopreventive eﬀects by modulating both phase I and phase
II enzymes. In the present study, we conﬁrmed the chemopre-
ventive eﬀects of eugenol in DMBA-treated MCF-7 cells and
also investigated the mechanism of the action.
DMBA is a procarcinogen that requires metabolic conver-
sion to its ultimate carcinogen metabolite, DMBA-3,4-dihy-
drodiol-1,2-epoxide [7], by either CYP1A1 and CYP1B1
[6,7]. DMBA can induce these CYPs through AhR-mediated
transcriptional activation for its own activation to reactive
metabolites. Our results showed that eugenol inhibits the
induction by DMBA of both EROD activity (Fig. 2A) andCYP1A1 and 1B1 mRNAs expression (Fig. 2B). Therefore,
we can conclude that the chemopreventive eﬀects of eugenol
are in part due to the suppression of carcinogen activating
CYP1 enzymes. Interestingly, we also demonstrated that euge-
nol can directly inhibit the CYP1A activity in microsomes
(Table 1). This direct inhibition may enhance the chemopre-
ventive eﬀects of eugenol on DMBA-induced carcinogenesis.
Similar CYP inhibition has been reported for dibenzoylme-
thane [32], curcumin [33] and oltipraz [34].
The CYP1A1 and CYP1B1 genes are normally regulated at
the transcription level via the binding of the ligand-activated
AhR to the XRE in the promoter region [9,10]. Therefore,
inhibiting the AhR-mediated signals transduction would pre-
vent the DMBA-induced biological damage. This study tested
the eﬀect of eugenol on XRE-mediated transcription and
found that it suppressed the up-regulation of the XRE-con-
trolled transcription by DMBA (Fig. 3A). An EMSA assay
was performed to further determine if eugenol aﬀects the bind-
ing of activated (ligand-bound) AhR to the XREs present in
the promoter regions of the CYP1 genes. As shown in
Fig. 3, eugenol inhibited the binding of the DMBA-activated
AhR to the XRE. This shows that the suppression of CYP1
mRNA expressions by eugenol is the result of the interruption
of AhR transactivation. We used murine version of XRE in
the transfection of reporter plasmids. Considering that many
previous reports have repeatedly shown the similarity of
XRE-mediated transcriptional regulation between murine
E.H. Han et al. / FEBS Letters 581 (2007) 749–756 755and human, we can expected that the same eﬀect of eugenol is
expected for the human CYP1 promoters. This expectation
was ascertained by the observation of CYP1A suppression
by eugenol in human MCF7 cells (Fig. 2). The present study
is the ﬁrst demonstration of eugenol as a potent inhibitor of
the AhR, which can block signal transduction initiated by
DMBA exposure. Therefore, eugenol may be a promising che-
mopreventive compound that targets the AhR.
The induction of the phase II enzymes by chemicals or die-
tary factors has been linked to cancer chemoprevention [1,3].
Our study clearly demonstrated that eugenol also has the
capacity to increase the expression of QR responsible for the
detoxiﬁcation of DMBA. We also conﬁrmed the transcrip-
tional activation of QR was mediated through Nrf2 binding
to an ARE sequence located at 5 0-upstream of human QR
gene (Fig. 5). Together with the direct inhibition and the sup-
pressive property of eugenol on CYP1 enzymes, the phase II
enzyme induction by eugenol may reinforce the chemopreven-
tive eﬀect of this compound. In separate experiment, we also
tested whether eugenol can modulate the expression of other
phase II enzyme, GSTA. The expression of GSTA was also
up-regulated by eugenol at transcriptional level and the mech-
anism of GSTA induction by eugenol was similar to that of
QR induction (data not shown). We can expect the chemopro-
tection of eugenol against carcinogenesis of GSTA substrate
compounds as well as QR substrates. Therefore, our data to-
gether with other reports [20,21] suggest that the consumption
of eugenol may be linked to cancer prevention.
In conclusion, our results demonstrate that eugenol reduced
the levels of DMBA–DNA adduct formation in the breast
cancer cell line, MCF-7 through at least three diﬀerent mecha-
nisms, the direct inhibition and suppression of DMBA-activat-
ing enzymes and the induction of DMBA detoxiﬁcation
enzymes. Considering the wide range of procarcinogens acti-
vated by CYP1 and carcinogens inactivated by QR and
GST, eugenol may have general chemopreventive features to
many carcinogens as well as DMBA. One advantage of euge-
nol as chemopreventive agents in human trials is that, unlike
synthetic chemopreventive agents, it is a naturally occurring
compound that is produced endogenously in plants.
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